BOME Therapeutics

Biotechnology Research • • 1-10 Employees

Company overview

Headquarters	XX
Website	bomepharma.com
NAICS	541714
Keywords	Immunotherapy, Allergy Treatment, Biotech Innovation, Antigen Development, Poison Ivy And Oak Relief
Founded	2022
Employees	1-10

Key Contact at BOME Therapeutics

Robert Coifman

Founder & Chief Science Officer

About BOME Therapeutics

BOME Therapeutics is disrupting allergen immunotherapy. At BOME Therapeutics, we are driven by a mission to revolutionize Allergen Immunotherapy. Our team has developed new methods and processes to create highly effective therapies to achieve patient tolerance to poison ivy and poison oak, plants long thought impossible to treat with immunotherapy. We believe our novel discoveries may result in additional applications and vaccine solutions which we hope to advance and make available to treat difficult and negatively impacted patients around the world.

BOME Therapeutics revenue & valuation

Annual revenue	$171,110
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$547,552
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Founder/Owner

Employees by Department

BOME Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

BOME Therapeutics has never raised funding before.

Frequently asked questions

BOME Therapeutics is located in XX.

BOME Therapeutics was founded in 2022, making it 4 years old. The company has established itself as a significant player in its industry over this time.

BOME Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at BOME Therapeutics

Robert Coifman

Founder & Chief Science Officer

4.8

40,000 users